Anne Stone1, Danielle Novetsky Friedman2, Brian H Kushner2, Suzanne Wolden3, Shakeel Modak2, Michael P LaQuaglia4, Jessica Costello5, Xian Wu6, Nai-Kong Cheung2, Charles A Sklar2. 1. Department of Pediatrics, Division of Pulmonology, Oregon Health and Science University, Portland, Oregon. 2. Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York. 3. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. 4. Department of Surgery and Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York. 5. Department of Pediatrics, Division of Pulmonology, Allergy and Immunology, New York, New York. 6. Department of Healthcare Policy and Research, Division of Biostatistics and Epidemiology, Weill Cornell Medical College, New York, New York.
Abstract
BACKGROUND/ OBJECTIVES: Survivors of high-risk neuroblastoma (NB) are exposed to multimodality therapies early in life and confront late therapy-related toxicities. This study assessed respiratory symptoms, exercise capacity, and longitudinal changes in pulmonary function tests (PFTs) among survivors. DESIGN/ METHODS: Survivors of high-risk NB followed in the long-term follow-up clinic at Memorial Sloan Kettering Cancer Center were enrolled. Symptom and physical activity questionnaires were completed. Medical records were reviewed for treatments and comorbidities. Participants completed spirometry, plethysmography, diffusion capacity of the lung for carbon monoxide, 6-minute walk tests (6MWTs), and cardiopulmonary exercise testing. Questionnaires and PFTs were repeated at least one year after enrollment. RESULTS: Sixty-two survivors participated (median age at study: 10.92 years; median age at diagnosis: 2.75 years; median time since completion of therapy: 5.29 years). Thirty-two percent had chronic respiratory symptoms. Seventy-seven percent had PFT abnormalities, mostly mild to moderate severity. Thirty-three completed 6MWTs (median, 634.3 meters); eight completed cardiopulmonary exercise tests (mean VO2 max: 63% predicted); 23 completed a second PFT revealing declines over a median 2.97 years (mean percent predicted forced vital capacity: 79.9 to 70.0; mean forced expiratory volume in 1 second: 81.6 to 69.9). Risks for abnormalities included thoracic surgery, chest radiation therapy (RT), thoracic surgery plus chest RT, and hematopoietic stem cell transplant. CONCLUSIONS: In this cohort of survivors of high-risk NB, PFT abnormalities were common but mostly mild or moderate. Maximal exercise capacity may be affected by respiratory limitations and declines in lung function may occur over time. Continued pulmonary surveillance of this at-risk population is warranted.
BACKGROUND/ OBJECTIVES: Survivors of high-risk neuroblastoma (NB) are exposed to multimodality therapies early in life and confront late therapy-related toxicities. This study assessed respiratory symptoms, exercise capacity, and longitudinal changes in pulmonary function tests (PFTs) among survivors. DESIGN/ METHODS: Survivors of high-risk NB followed in the long-term follow-up clinic at Memorial Sloan Kettering Cancer Center were enrolled. Symptom and physical activity questionnaires were completed. Medical records were reviewed for treatments and comorbidities. Participants completed spirometry, plethysmography, diffusion capacity of the lung for carbon monoxide, 6-minute walk tests (6MWTs), and cardiopulmonary exercise testing. Questionnaires and PFTs were repeated at least one year after enrollment. RESULTS: Sixty-two survivors participated (median age at study: 10.92 years; median age at diagnosis: 2.75 years; median time since completion of therapy: 5.29 years). Thirty-two percent had chronic respiratory symptoms. Seventy-seven percent had PFT abnormalities, mostly mild to moderate severity. Thirty-three completed 6MWTs (median, 634.3 meters); eight completed cardiopulmonary exercise tests (mean VO2 max: 63% predicted); 23 completed a second PFT revealing declines over a median 2.97 years (mean percent predicted forced vital capacity: 79.9 to 70.0; mean forced expiratory volume in 1 second: 81.6 to 69.9). Risks for abnormalities included thoracic surgery, chest radiation therapy (RT), thoracic surgery plus chest RT, and hematopoietic stem cell transplant. CONCLUSIONS: In this cohort of survivors of high-risk NB, PFT abnormalities were common but mostly mild or moderate. Maximal exercise capacity may be affected by respiratory limitations and declines in lung function may occur over time. Continued pulmonary surveillance of this at-risk population is warranted.
Authors: Daniel M Green; Liang Zhu; Mingjuan Wang; Kirsten K Ness; Matthew J Krasin; Nickhill H Bhakta; M Beth McCarville; Saumini Srinivasan; Dennis C Stokes; DeoKumar Srivastava; Rohit Ojha; Kyla Shelton; Ching-Hon Pui; Gregory T Armstrong; Daniel A Mulrooney; Monika Metzger; Sheri L Spunt; Fariba Navid; Andrew M Davidoff; Bhaskar N Rao; Leslie L Robison; Melissa M Hudson Journal: Ann Am Thorac Soc Date: 2016-09
Authors: Rajkumar Venkatramani; Sunil Kamath; Kenneth Wong; Arthur J Olch; Jemily Malvar; Richard Sposto; Fariba Goodarzian; David R Freyer; Thomas G Keens; Leo Mascarenhas Journal: Pediatr Blood Cancer Date: 2014-01-31 Impact factor: 3.167
Authors: C Ferry; G Gemayel; V Rocha; M Labopin; H Esperou; M Robin; R P de Latour; P Ribaud; A Devergie; T Leblanc; E Gluckman; A Baruchel; G Socié Journal: Bone Marrow Transplant Date: 2007-05-28 Impact factor: 5.483
Authors: Gregory T Armstrong; Qi Liu; Yutaka Yasui; Joseph P Neglia; Wendy Leisenring; Leslie L Robison; Ann C Mertens Journal: J Clin Oncol Date: 2009-03-30 Impact factor: 44.544
Authors: Eline van Dulmen-den Broeder; Margreet A Veening; Katja I Braam; Elisabeth M van Dijk-Lokkart; Gertjan J L Kaspers; Tim Takken; Jaap Huisman; Marc B Bierings; Johannes H M Merks; Marry M van de Heuvel-Eibrink Journal: Support Care Cancer Date: 2015-11-19 Impact factor: 3.359